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Wound	  healing	  constitutes	  a	  brief	  inflammatory	  phase,	  followed	  by	  proliferative	  phase	  and	  ends	  
with	   a	   longer	   period	   of	   tissue	   remodeling.	   Post	   tissue	   injury,	   macrophages	   initiate	   an	  
inflammatory	   cascade	   to	   propagate	   wound	   healing.	   Macrophages	   initially	   adapt	   a	   pro-­‐
inflammatory	  “M1”	  activation	  state,	  followed	  an	  anti-­‐inflammatory	  “M2”	  macrophages	  that	  are	  
associated	  with	  the	  resolution	  of	  initial	  inflammation.	  The	  M1-­‐to-­‐M2	  transition	  has	  been	  shown	  
to	  be	  crucial	  to	  facilitate	  healing.	  Impairment	  of	  this	  phenotypic	  switch	  is	  associated	  with	  chronic	  
inflammation.	  Chronic	   inflammation	   is	  characterized	  by	  a	  sustained	  M1.	  Noteworthy,	  patients	  
suffering	  from	  chronic	  inflammatory	  conditions	  have	  a	  systemically	  higher	  that	  normal	  LPS	  levels,	  
which	  is	  thought	  to	  trigger	  chronic	  and	  systemic	  pro-­‐inflammatory	  activation	  of	  macrophages.	  
Surprisingly,	  while	  normal	  wounds	  posses	  an	   initial	   and	   robust	   inflammatory	   reaction,	   recent	  
studies	  have	  highlighted	  that	  chronic	  wounds	  suffer	  lower	  than	  normal	  initial	  inflammatory	  state	  
in	  response	  to	  otherwise	  potent	  pro-­‐inflammatory	  stimulation.	  The	  goal	  of	  this	  work	  is	  to	  study	  
the	  impact	  of	  chronic	  LPS	  stimulation	  on	  macrophages	  pro-­‐inflammatory	  reaction	  to	  a	  fresh	  LPS	  
treatment	  and	  its	  subsequent	  capacity	  to	  respond	  to	  IL4/IL13,	  “M2”	  promoting	  cytokines.	  This	  
work	  highlighted	  	  	  that	  chronic	  LPS	  stimulation	  rendered	  macrophages	  hypo-­‐responsive	  to	  fresh	  
LPS	   stimulation.	   However,	   it	   did	   not	   impact	   their	   “M2”	   switching	   capacity.	   IFNg,	   a	   pro-­‐
inflammatory	   cytokine,	   treatment	   of	   chronic	   “M1”	   macrophages	   did	   not	   improve	   their	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1.   Introduction	  
	  
Macrophages	  are	  indispensable	  innate	  immune	  cells,	  which	  orchestrate	  a	  multitude	  of	  
functions	  in	  our	  bodies	  ranging	  from	  fighting	  infections	  and	  clearing	  debris	  to	  promoting	  tissue	  
healing	  and	  angiogenesis1.	  Their	  significant	  role	  in	  tissue	  regeneration	  and	  angiogenesis	  has	  
been	  increasingly	  recognized	  2-­‐5.	  While	  the	  mechanism	  in	  which	  they	  promote	  healing	  is	  not	  
well	  understood,	  evidence	  indicates	  that	  macrophage	  depletion	  has	  detrimental	  effects	  on	  
healing	  in	  various	  tissue	  types	  including	  the	  skin5,	  heart6,	  cornea7	  and	  liver8.	  
In	  response	  to	  tissue	  injury,	  tissue	  resident	  macrophages	  initiate	  an	  inflammatory	  cascade	  
that	  mediates	  the	  recruitment	  of	  neutrophils	  and	  then	  monocytes	  into	  the	  injury	  site9.	  Upon	  
the	  arrival	  of	  monocytes	  to	  the	  tissue,	  they	  mature	  into	  macrophages10,11.	  Macrophages	  initially	  
adapt	  a	  pro-­‐inflammatory	  “M1”	  activation	  state	  12,13	  ,	  which	  can	  be	  mimicked	  in	  vitro	  using	  Th1	  
cytokines	  like	  interferon	  gamma	  (IFNg)	  or	  bacterial	  lipopolysaccharides	  (LPS)14.	  M1	  
macrophages	  are	  characterized	  by	  their	  secretion	  of	  pro-­‐inflammatory	  cytokines,	  including	  
tumor	  necrosis	  factor	  alpha	  (TNF-­‐a),	  interleukin	  beta	  (IL1-­‐B),	  and	  the	  potent	  angiogenesis	  
stimulator	  vascular	  endothelial	  growth	  factor	  (VEGF)15.	  	  	  
Acute	  inflammation,	  initiated	  by	  M1	  macrophages,	  facilitates	  the	  proper	  propagation	  of	  
wound	  healing16.	  	  Besides	  the	  established	  role	  of	  inflammation	  in	  clearing	  debris	  and	  bacteria,	  it	  
has	  been	  shown	  to	  play	  a	  role	  in	  tissue	  vascularization	  15,17.	  However,	  a	  prolonged	  inflammatory	  
state	  is	  problematic	  and	  impairs	  healing	  18.	  Therefore,	  in	  healthy	  wound	  healing,	  an	  acute	  
period	  of	  inflammation	  resolves	  over	  time	  and	  is	  accompanied	  with	  a	  shift	  in	  the	  macrophage	  
population	  from	  pro-­‐inflammatory	  “M1”	  to	  anti-­‐inflammatory	  “M2”	  13,19.	  M2	  macrophages	  are	  
12  
associated	  with	  resolution	  of	  inflammation,	  cellular	  proliferation,	  and	  blood	  vessel	  maturation	  
15,20	  .	  M2	  macrophages	  can	  be	  generated	  in	  vitro	  using	  Th2	  cytokines	  such	  as	  interleukin	  4	  and	  
interleukin	  13	  (IL4/13)14,	  and	  they	  secrete	  various	  chemokines	  like	  CCL18,	  CCL22,	  and	  growth	  




Figure	  1.	  Wound	  healing	  phases	  modulated	  by	  macrophages	  M1-­‐to-­‐M2	  transition12,13	  
13  
	  
The	  M1-­‐to-­‐M2	  shift	  is	  temporally	  controlled	  to	  facilitate	  the	  proper	  progression	  of	  wound	  
healing	  stages,	  starting	  with	  a	  brief	  phase	  of	  inflammation	  followed	  by	  cellular	  proliferation	  and	  
ending	  with	  a	  longer	  period	  of	  remodeling	  (Figure	  1)12,13.	  The	  mechanism	  of	  macrophage	  
transition	  from	  M1-­‐to-­‐	  M2	  macrophage	  in	  an	  injury	  site	  remains	  controversial;	  while	  some	  
evidence	  suggest	  that	  recruitment	  of	  a	  new	  wave	  of	  M2	  macrophages	  plays	  a	  major	  role21,22,	  
others	  suggest	  that	  macrophage	  repolarization	  via	  local	  signals	  is	  the	  important	  mechanism	  
contributing	  to	  the	  M1-­‐to-­‐	  M2	  transition	  21,23,24.	  
	  
1.1.   M1-­‐to-­‐M2	  transition	  in	  vivo	  
	  
M1	  macrophages	  are	  the	  first	  subtype	  of	  macrophages	  that	  reacts	  to	  tissue	  injury	  and	  
initiate	  the	  inflammatory	  response13.	  While	  their	  fate	  over	  time	  is	  not	  well	  understood,	  in	  vivo	  
studies	  have	  suggests	  that	  they	  can	  repolarize	  to	  M2	  phenotype	  overtime.	  Arnold	  et	  al.13	  
showed	  the	  infiltration	  of	  M1	  macrophages	  to	  a	  skeletal	  muscle	  injury	  was	  followed	  by	  dynamic	  
switch	  to	  the	  M2	  phenotype.	  Their	  results	  suggested	  that	  both	  recruitment	  and	  local	  
conditioning	  were	  essential	  for	  the	  M1-­‐to-­‐M2	  transition13.	  Additionally,	  Del	  Secco	  et	  al.23	  used	  
sophisticated	  fluorescent	  labeling	  techniques	  to	  image	  macrophage	  phenotypes	  in	  a	  sterile	  liver	  
wound	  murine	  model	  over	  time23.	  Their	  data	  indicated	  that	  M1	  macrophages	  dominate	  the	  
wound	  site	  initially	  23.	  As	  healing	  progressed,	  some	  macrophages	  switched	  their	  surface	  
markers	  from	  M1	  to	  M2	  associated	  markers,	  while	  others	  expressed	  a	  hybrid	  of	  both	  M1	  and	  
M2	  surface	  markers23,	  suggesting	  an	  M1-­‐to-­‐M2	  transition	  of	  individual	  cells.	  Interestingly,	  
blocking	  IL10	  or	  IL14	  cytokines	  delayed	  the	  shift	  from	  M1	  phenotype	  to	  a	  hybrid	  and	  M2	  
14  
phenotypes	  indicating	  the	  importance	  of	  local	  cytokines	  in	  facilitating	  the	  M1-­‐to-­‐M2	  switch23.	  
Interestingly,	  they	  did	  not	  observe	  any	  M2	  macrophages	  infiltrating	  the	  site	  over	  the	  duration	  
of	  this	  experiment	  suggesting	  the	  importance	  of	  local	  cytokines	  in	  the	  generation	  of	  M2	  
macrophages23.	  
	  
1.2.   Macrophage	  exhaustion	  in	  chronic	  inflammatory	  diseases	  
	  
Chronic	  inflammatory	  diseases	  are	  characterized	  by	  an	  impaired	  M1-­‐to-­‐M2	  transition18,25,26.	  
Mechanisms	  leading	  to	  this	  impairment	  remains	  elusive.	  A	  common	  theme	  across	  many	  chronic	  
inflammatory	  conditions	  including	  inflammatory	  bowl	  diseases27,	  diabetes28	  and	  
hyperlipidemia29,30	  ,	  is	  the	  systemic	  increase	  in	  LPS	  levels.	  The	  systemic	  increase	  in	  LPS	  is	  
thought	  to	  originate	  from	  gut	  derived	  commensal	  bacteria	  that	  is	  leaked	  to	  the	  circulatory	  
system	  due	  to	  intestinal	  permeability	  which	  is	  triggered	  by	  the	  increased	  consumption	  of	  high	  
fat	  diet	  and	  environmental	  toxins	  prevalent	  in	  the	  modern	  life	  style	  28,31,32.	  
Macrophages	  in	  people	  with	  higher	  systemic	  LPS	  levels	  are	  characterized	  by	  	  M1	  associated	  
surface	  markers,	  including	  Tol-­‐like	  receptor	  33-­‐40.	  For	  example,	  it	  has	  been	  indicated	  that	  newly	  
diagnosed	  patients	  with	  diabetes	  posses	  a	  higher	  level	  of	  systemic	  Tol-­‐Like	  receptor	  2	  and	  4	  
(TLR2/4),	  which	  are	  major	  LPS	  receptors,	  and	  correlated	  with	  increased	  LPS	  levels	  and	  pro-­‐
inflammatory	  cytokines	  41.	  	  However,	  although	  higher	  LPS	  levels	  has	  been	  associated	  with	  
increased	  systemic	  pro-­‐inflammatory	  markers	  initially,	  its	  chronic	  effects	  on	  macrophages	  
remain	  elusive.	  Some	  evidence	  suggests	  that	  although	  LPS	  levels	  are	  high	  in	  patients	  
susceptible	  to	  developing	  diabetic	  complications	  42,	  those	  patients	  exhibit	  a	  lower	  level	  of	  
systemic	  pro-­‐inflammatory	  cytokines	  relative	  to	  other	  diabetic	  patients	  without	  complications	  
15  
40.	  	  Since	  the	  risk	  of	  developing	  complications	  increases	  with	  poor	  disease	  management	  for	  
prolonged	  duration	  42,	  such	  observation	  suggests	  that	  the	  pro-­‐inflammatory	  reaction	  to	  LPS	  
decreases	  with	  time.	  The	  observed	  reduction	  in	  macrophages	  pro-­‐inflammatory	  cytokine	  
secretion	  in	  patients	  in	  response	  to	  prolonged	  LPS	  stimulation	  43-­‐45,	  could	  be	  possibly	  explained	  
by	  macrophage	  exhaustion.	  Immune	  exhaustion	  has	  been	  defined	  by	  the	  inability	  of	  immune	  
cells	  to	  mount	  a	  proper	  immune	  reaction	  to	  a	  pro-­‐inflammatory	  signal	  due	  to	  its	  chronic	  
activation46	  by	  factors	  like	  chronic	  diseases47	  and	  aging	  46.	  	  	  
Of	  the	  immune	  cells,	  most	  studies	  focused	  on	  T	  cell	  exhaustion	  48.	  For	  example,	  In	  
chronic	  viral	  infections,	  CD8	  T-­‐cells	  loss	  their	  capacity	  to	  perform	  their	  cytotoxic	  functions	  or	  
proliferate48.	  Additionally,	  they	  are	  resistant	  to	  apoptosis	  and	  accumulate	  in	  high	  numbers48.	  
Indeed,	  the	  accumulation	  of	  exhausted	  CD8	  T-­‐cells	  in	  chronic	  infections	  predicts	  the	  severity	  of	  
the	  disease48.	  	  CD8	  T-­‐cells	  in	  chronic	  diseases	  are	  exhausted	  due	  to	  the	  programmed	  cell	  death-­‐
1	  receptor	  (PD-­‐1)	  and	  PD-­‐L1	  ligand	  interactions	  that	  activate	  immune	  inhibitory	  signaling	  49.	  
Blockade	  of	  PD-­‐1/PD-­‐L1	  interactions	  has	  been	  shown	  successful	  in	  restoring	  exhausted	  CD8	  T-­‐
cells	  functions	  50.	  	  
Unlike,	  CD8	  T-­‐cell	  exhaustion,	  	  macrophage	  exhaustion	  remains	  less	  understood	  43.	  
Recently,	  a	  similar	  increase	  in	  PD-­‐1	  expression	  has	  been	  described	  in	  macrophages	  treated	  with	  
LPS	  	  for	  24	  hours43.	  However,	  the	  effect	  of	  chronic	  LPS	  stimulation	  was	  not	  directly	  tested.	  
Additionally,	  the	  increased	  PD-­‐1	  expression	  was	  shown	  to	  be	  associated	  with	  an	  increase	  in	  IL10	  
production	  51.	  A	  recent	  study	  showed	  the	  importance	  of	  IL-­‐10	  signaling	  in	  the	  maintenance	  of	  
the	  exhausted	  macrophage	  phenotype	  and	  the	  development	  of	  pathological	  angiogenesis	  in	  
chronic	  eye	  disease	  model	  52.	  It	  was	  also	  shown	  that	  exhausted	  macrophages	  posses	  hyper-­‐
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responsiveness	  to	  IL10	  signaling52.	  Interestingly,	  it	  was	  shown	  that	  inhibiting	  IL-­‐10/STAT3	  
signaling	  may	  have	  the	  potential	  to	  rescue	  exhausted	  macrophages52.	  	  
	  Similar	  to	  macrophage	  exhaustion,	  a	  hypo-­‐responsive	  macrophage	  response	  has	  been	  
described	  in	  cases	  of	  tolerance.	  However,	  macrophage	  tolerance	  is	  a	  more	  understood	  
macrophage	  behavior.	  It	  is	  a	  state	  of	  macrophage	  hypo	  responsiveness	  to	  pro-­‐inflammatory	  
stimulations	  post	  a	  high	  and	  acute	  and	  high	  TNFa	  or	  LPS	  stimulation53,54.	  Short-­‐term	  exposure	  
to	  LPS	  (1	  hr	  -­‐to-­‐	  8	  hr)	  was	  shown	  to	  be	  sufficient	  to	  induce	  some	  macrophage	  hypo-­‐
responsiveness	  to	  secondary	  LPS	  stimulation55.	  The	  tolerant	  macrophage	  memory	  can	  be	  
maintained	  up	  to	  ∼5	  days	  post	  treatment	  55.	  The	  tolerant	  state	  is	  thought	  to	  be	  mediated	  by	  IL-­‐
10	  and	  transforming	  growth	  factor	  TGF-­‐B	  production	  by	  macrophages	  during	  their	  primary	  LPS	  
stimulation	  56.	  However,	  a	  clear	  distinction	  between	  exhaustion	  and	  tolerance	  is,	  while	  tolerant	  
macrophage	  state	  is	  known	  to	  be	  a	  temporary	  state	  that	  abolish	  with	  time57,	  immune-­‐	  
exhaustion	  is	  thought	  to	  cause	  a	  prolonged	  state	  of	  immune	  hypo-­‐responsiveness58.	  
Attempts	  to	  rescue	  tolerance	  includes	  using	  IFNg	  ,	  a	  pro-­‐inflammatory	  cytokine	  
treatment.	  It	  has	  been	  indicated	  that	  interferon	  gamma	  partially	  inhibits	  the	  negative	  feedback	  
loop	  induced	  by	  LPS	  tolerant	  macrophages59,60.	  	  Additionally,	  IFNg	  treatment,	  partially	  restored	  
energy	  metabolism	  and	  cytokine	  production	  capability	  in	  tolerant	  macrophgaes61.	  Interestingly,	  	  
IFNg	  treatment	  has	  been	  also	  shown	  to	  rescue	  macrophages	  capacity	  to	  phagocytose	  dead	  cells	  
in	  chronic	  granulomatous62.	  Additionally,	  IFNg	  has	  been	  previously	  shown	  to	  inhibit	  IL10	  
secretion	  from	  macrophages63.	  Since	  more	  research	  is	  available	  on	  macrophage	  tolerance,	  and	  
owing	  to	  the	  similarities	  between	  tolerance	  and	  exhaustion	  of	  macrophages58,61,	  delivering	  IFNg	  
may	  have	  the	  potential	  to	  rescue	  macrophage	  exhaustion	  and	  promote	  the	  proper	  M1	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response	  that	  is	  impaired	  in	  chronic	  inflammation.	  
	  
1.3.   Impaired	  macrophage	  inflammatory	  functions	  in	  chronic	  inflammation	  
	  
It	  is	  thought	  that	  macrophage	  exhaustion	  due	  to	  aging	  or	  chronic	  diseases	  is	  the	  cause	  
for	  impaired	  macrophage	  functions	  44.	  For	  example,	  injecting	  allogenic	  macrophages	  from	  
young	  donors,	  not	  old	  ones,	  to	  patients	  with	  chronic	  wounds	  showed	  improved	  healing	  
outcomes,	  suggesting	  that	  macrophages	  from	  older	  patient	  are	  reaching	  an	  exhausted	  phase,	  
impairing	  their	  wound	  healing	  functions64.	  However,	  to	  our	  knowledge,	  the	  direct	  impact	  of	  
chronic	  pro-­‐inflammatory	  stimulation	  of	  macrophages	  functions	  is	  poorly	  understood.	  Recently,	  
increased	  chronic	  LPS	  levels	  have	  been	  directly	  linked	  to	  impaired	  tissue	  healing65.	  For	  example,	  
Yuan	  et	  al65	  injected	  mice	  with	  LPS	  or	  phosphate	  buffered	  saline	  (PBS)	  for	  10	  days,	  then	  induced	  
a	  full	  thickness	  cutaneous	  injury65.	  Vascularization	  and	  collagen	  deposition	  were	  significantly	  
reduced	  in	  mice	  chronically	  stimulated	  with	  LPS65.	  Vascularization	  and	  collagen	  deposition	  are	  
both	  associated	  with	  M1	  and	  M2	  functions	  in	  normal	  wound	  healing15,20,	  suggesting	  that	  
macrophage	  impairment	  is	  linked	  to	  the	  impaired	  healing	  response65.	  
Nassiri	  et	  al25	  compared	  the	  temporal	  expression	  of	  pro-­‐inflammatory	  and	  anti-­‐
inflammatory	  markers	  in	  diabetic	  human	  ulcers.	  Interestingly,	  	  they	  showed	  that	  non-­‐healing	  
ulcers	  had	  an	  initially	  lower	  pro-­‐inflammatory	  gene	  expression	  signatures	  relative	  to	  healing	  
ulcers	  25.	  However,	  non-­‐healing	  ulcers	  increased	  	  their	  pro-­‐inflammatory	  gene	  expression	  
signature	  overtime,	  unlike	  healing	  ulcers25.	  This	  study	  suggests	  that	  patients	  that	  develops	  
chronic	  wounds	  complications,	  have	  lower	  capacity	  to	  mount	  a	  rapid	  and	  robust	  inflammatory	  
response	  in	  response	  to	  injury.	  Similarly,	  Marks	  et	  al.66	  showed	  that	  patients	  with	  inflammatory	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bowl	  disease	  express	  defective	  acute	  inflammatory	  response66.	  Their	  peripheral	  blood	  
monocytes	  were	  isolated,	  cultured	  in	  vitro	  and	  stimulated	  with	  TNFa	  or	  with	  wound	  fluid	  
gathered	  from	  the	  early	  inflammatory	  phase	  from	  healthy	  individuals66.	  Patients’	  macrophages	  
expressed	  significantly	  less	  pro-­‐inflammatory	  cytokine	  in	  response	  to	  either	  stimulation	  relative	  
to	  healthy	  macrophages66	  .	  Similarly,	  Malaponte	  et	  al.67	  	  showed	  that	  continuous	  inflammatory	  
stimulation	  by	  dialysis	  treatment	  caused	  impaired	  response	  of	  macrophages	  to	  inflammatory	  
stimulation,	  which	  was	  directly	  proportional	  to	  the	  number	  of	  months	  they	  have	  been	  
undergoing	  dialysis.	  They	  quantified	  pro-­‐inflammatory	  cytokines	  released	  into	  plasma	  of	  
healthy	  patients	  and	  patients	  that	  go	  through	  dialysis	  treatments	  before	  and	  after	  treatment67.	  
The	  patients	  were	  categorized	  into	  patients	  that	  have	  been	  going	  through	  dialysis	  treatments	  
for	  short,	  medium	  and	  long	  time67.	  The	  results	  showed	  that	  ability	  of	  macrophages	  to	  secrete	  
pro-­‐inflammatory	  cytokines	  in	  vivo	  and	  in	  vitro	  in	  response	  to	  LPS	  was	  inversely	  proportional	  to	  
the	  time	  of	  dialysis	  treatment67.	  These	  results	  suggest	  that	  chronic	  pro-­‐inflammatory	  
stimulation	  exhausts	  inflammatory	  capacity	  of	  macrophages	  in	  response	  to	  fresh	  pro-­‐
inflammatory	  stimulation.	  Collectively,	  these	  studies	  suggest	  the	  impaired	  M1	  response	  in	  
chronic	  inflammatory	  cases	  consequently	  impairs	  the	  propagation	  of	  wound	  healing68.	  	  
	  Since	  the	  the	  proper	  wound	  healing	  response	  has	  been	  associated	  with	  a	  temporally	  
controlled	  	  M1-­‐to-­‐M2	  switch	  	  in	  macrophage	  phenotypes,	  many	  researchers	  investigated	  
possible	  ways	  to	  facilitate	  this	  process	  by	  using	  local	  cytokines	  delivery	  in	  order	  to	  override	  
impaired	  macrophages	  behavior	  in	  disease15.	  	  
	  
1.4.   M1-­‐to-­‐M2	  switching	  in	  vitro	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The	  impaired	  M1-­‐to-­‐M2	  macrophages	  shift	  in	  chronic	  inflammatory	  conditions	  
motivated	  further	  investigations	  to	  highlight	  the	  plasticity	  of	  macrophages,	  defined	  by	  their	  
capacity	  to	  respond	  to	  different	  and	  sequential	  environmental	  stimulations	  by	  changing	  their	  
phenotype.	  	  
In	  vitro	  evidence	  suggest	  that	  pro-­‐inflammatory	  and	  un-­‐activated	  macrophages	  have	  the	  
capacity	  to	  make	  anti-­‐inflammatory	  “M2”	  macrophages	  upon	  stimulation	  with	  IL4/IL13	  
cytokines15.	  Macrophages	  gene	  expression,	  surface	  marker	  expression,	  and	  protein	  secretion	  
have	  been	  shown	  to	  reflect	  their	  response	  to	  the	  most	  recent	  stimuli15.	  Moreover,	  Porcheray	  et	  
al69	  questioned	  the	  if	  the	  M2	  macrophage	  population	  originated	  from	  previously	  resting	  
macrophage,	  or	  if	  they	  arise	  from	  an	  initially	  pro-­‐inflammatory	  M1	  macrophages	  population.	  
They	  suggested	  that	  the	  heterogeneity	  of	  M2	  macrophages	  allude	  to	  the	  concept	  that	  the	  M1	  
to	  M2	  switching	  is	  an	  important	  contributor	  to	  the	  complexity	  of	  the	  M2	  population.	  They	  
treated	  macrophages	  with	  TNFa	  to	  promote	  M1	  followed	  by	  transforming	  growth	  factor	  beta	  
(TGF-­‐B),	  interleukin	  10	  or	  4	  (IL10,	  IL4)	  treatments	  to	  promote	  the	  sequential	  M1-­‐to-­‐M2	  
transition69.	  They	  observed	  changes	  in	  macrophage	  surface	  markers	  and	  morphologies	  in	  
response	  to	  different	  treatments	  to	  reflect	  their	  M2	  phenotype69.	  Their	  data	  showed	  that	  
macrophages	  were	  fully	  and	  actively	  reversing	  from	  M1	  	  phenotype	  to	  M2	  	  phenotypes69.	  	  
These	  significant	  findings	  suggest	  that	  M1-­‐to-­‐M2	  phenotype	  switching	  could	  be	  a	  mechanism	  to	  
resolve	  inflammation69.	  
Additionally,	  Davis	  et	  al.	  70	  showed	  that	  macrophage	  repolarization	  in	  response	  to	  
cryptococcal	  pneumonia	  is	  part	  of	  the	  pathology	  of	  this	  infection.	  They	  noted	  that	  lung	  
macrophages	  changed	  their	  phenotype	  over	  the	  duration	  of	  the	  infection	  in	  response	  to	  the	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invading	  pathogen	  in	  a	  way	  that	  affected	  healing	  outcomes70.	  Macrophages	  dynamically	  
changed	  their	  gene	  expression,	  morphology,	  and	  protein	  secretion	  to	  reflect	  their	  sequential	  
response	  to	  IFNg	  then	  IL4	  stimulation70.	  Their	  study	  highlighted	  the	  potential	  importance	  of	  
developing	  therapies	  for	  controlling	  macrophages	  dynamic	  polarization	  in	  diseases	  to	  control	  
healing	  outcomes	  70.	  Similarly,	  Stout	  et	  al71	  treated	  macrophages	  with	  a	  variety	  of	  sequential	  
cytokines	  before	  being	  exposed	  to	  LPS	  to	  investigate	  macrophages	  functional	  adabtability	  and	  
capacity	  to	  sequentially	  change	  their	  phenotype71.	  They	  stimulated	  macrophages	  with	  different	  
cytokines	  including	  IL10	  ,	  IFNg	  or	  IL4.	  The	  differences	  in	  their	  response	  to	  the	  later	  LPS	  was	  
determined	  to	  be	  due	  to	  their	  memory	  from	  the	  previous	  type	  of	  cytokine	  treatment71.	  For	  
example,	  treating	  macrophages	  with	  IL4	  prior	  to	  being	  exposed	  to	  LPS	  significantly	  enhanced	  
their	  secretion	  of	  inflammatory	  cytokines	  including	  TNFa	  and	  reduced	  their	  anti-­‐inflammatory	  
cytokines	  secretion	  including	  IL1071.	  Their	  data	  suggested	  the	  capacity	  of	  macrophages	  to	  
functionally	  adapt	  to	  changing	  microenvironment	  by	  altering	  their	  protein	  secretion	  profile,	  
highlighting	  the	  effect	  of	  macrophages	  memory	  in	  modifying	  their	  response	  to	  subsequent	  
stimulations	  in	  some	  cases71.	  	  
	  
1.5.   Significance	  
	  
Post	  tissue	  damage,	  monocytes	  must	  traffic	  to	  the	  tissue	  and	  subsequently	  differentiate	  
to	  macrophages	  in	  order	  for	  wound	  healing	  to	  occur13.	  Macrophages	  play	  a	  major	  role	  in	  tissue	  
regeneration	  and	  wound	  healing	  and	  their	  dysfunctional	  behavior	  have	  been	  observed	  in	  
chronic	  inflammatory	  situations	  and	  impaired	  healing.	  Since	  LPS	  levels	  are	  systemically	  higher	  in	  
many	  chronic	  inflammatory	  diseases,	  we	  suspect	  that	  it	  may	  directly	  cause	  macrophage	  
exhausted	  response	  to	  fresh	  pro-­‐inflammatory	  and	  anti-­‐inflammatory	  environmental	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stimulation.	  Understanding	  the	  effect	  of	  chronic	  LPS	  stimulation	  on	  functional	  M1	  activation	  
and	  their	  subsequent	  M2	  transition	  is	  important	  because	  it	  could	  elucidate	  a	  potential	  reason	  
for	  the	  impaired	  M1-­‐to-­‐M2	  switch	  in	  chronic	  inflammation.	  In	  addition,	  since	  sequential	  
cytokines	  delivery	  is	  a	  potential	  therapy	  to	  facilitate	  the	  M1-­‐to-­‐M2	  transition	  15,72,	  it	  is	  
imperative	  to	  understand	  the	  impact	  of	  chronic	  LPS	  stimulation	  observed	  in	  patients,	  	  on	  their	  
macrophage’s	  ability	  to	  respond	  to	  fresh	  cytokines	  treatments	  which	  may	  inform	  the	  
development	  of	  more	  effective	  therapeutic	  strategies.	  
2.   Summary	  of	  Aims	  
	  
Macrophages,	  are	  central	  players	  in	  modulating	  the	  inflammatory	  and	  wound	  healing	  
response	  13.	  Their	  behavior	  was	  shown	  to	  be	  dysregulated	  by	  various	  chronic	  pathologies,	  
including	  diabetes	  68.	  In	  normal	  wound	  healing,	  macrophages	  behavior	  is	  temporally	  controlled	  
to	  possess	  a	  pro-­‐inflammatory	  “M1”	  phenotype	  at	  early	  stages	  post	  injury	  and	  an	  anti-­‐
inflammatory	  “M2”	  phenotype	  at	  later	  stages	  13.	  The	  impaired	  M1-­‐to-­‐M2	  shift	  has	  been	  shown	  
to	  be	  linked	  to	  chronic,	  non-­‐healing	  injuries	  25.	  However,	  factors	  causing	  this	  impairment	  
remain	  poorly	  understood.	  Since	  chronic	  pro-­‐inflammatory	  stimulation	  of	  macrophage	  is	  
linked	  to	  impaired	  healing65,	  we	  propose	  that	  macrophages	  exhaustion	  (hypo-­‐responsiveness	  
to	  environmental	  stimulation)	  mediates	  the	  delay	  in	  the	  initial	  inflammatory	  response,	  and	  
subsequently	  impair	  the	  propagation	  of	  the	  healing	  phases	  facilitated	  by	  the	  M1-­‐to-­‐M2	  
switch.	  	  We	  seek	  to	  delineate	  the	  effects	  of	  chronic	  macrophages	  exposure	  to	  LPS	  (M1	  
promoting	  stimuli)	  on	  their	  ability	  to	  respond	  to	  fresh	  LPS	  and	  subsequently	  to	  IL13/4(M2	  
promoting	  stimuli)	  to	  examine	  their	  M1-­‐to-­‐M2	  switching	  capacity.	  The	  first	  aim	  is	  to	  examine	  
the	  effect	  of	  chronic	  versus	  acute	  LPS	  stimulation	  on	  human	  monocytes	  and	  macrophages	  
22  
subsequent	  response	  to	  fresh	  LPS.	  We	  hypothesize	  that	  the	  chronic	  LPS	  stimulation	  of	  
monocytes	  and	  macrophages	  will	  decrease	  their	  response	  over	  time	  because	  they	  may	  develop	  
exhaustion	  leading	  to	  hypo-­‐responsiveness	  to	  environmental	  stimulation.	  The	  second	  aim	  is	  to	  
test	  the	  impact	  of	  chronic	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐M2	  transition	  capacity.	  We	  
expect	  that	  LPS	  chronic	  exposure	  will	  impair	  macrophages	  response	  to	  IL4/IL13	  by	  reducing	  
their	  PDGBB	  and	  CCL18	  protein	  secretion,	  which	  are	  common	  M2	  markers	  14,	  relative	  to	  acutely	  
stimulated	  and	  naïve	  macrophages	  that	  are	  exposed	  to	  IL13/4.	  The	  third	  aim	  of	  this	  work,	  is	  to	  
study	  the	  impact	  of	  a	  pro-­‐inflammatory	  cytokine	  treatment	  (IFNg)	  to	  restore	  the	  
responsiveness	  of	  exhausted	  macrophages	  to	  LPS	  and	  to	  IL13/IL4	  cytokines.	  We	  hypothesize	  
that	  similar	  to	  IFNg’s	  ability	  to	  partially	  restore	  macrophages	  functions	  in	  tolerant	  macrophages	  
59,	  IFNg	  may	  restore	  the	  responsiveness	  of	  exhausted	  macrophages,	  since	  both	  exhaustion	  and	  
tolerance	  are	  mediated	  by	  an	  inflammatory	  negative	  feedback	  mechanism.	  	  
	  
3.   Aim	  1.	  Determine	  the	  effect	  of	  chronic	  LPS	  stimulation	  on	  TNFa	  secretion	  of	  human	  
macrophages.	  
	  
3.1.   Background	  
	  
A	  common	  theme	  noted	  across	  patients	  with	  chronic	  inflammatory	  diseases	  is	  the	  
systemic	  and	  chronic	  increase	  in	  LPS	  levels	  73,74.	  Macrophages	  response	  to	  acute	  LPS	  stimulation	  
is	  well	  characterized.	  Their	  response	  is	  governed	  by	  a	  negative	  feedback	  loop	  which	  is	  initiated	  
a	  few	  hours	  following	  their	  first	  exposure	  to	  LPS,	  causing	  their	  pro-­‐inflammatory	  cytokines	  
secretion	  to	  subside	  overtime,	  and	  their	  anti-­‐inflammatory	  markers	  including	  CC-­‐chemokines	  
CCL22,	  CCL2	  and	  CCL17	  to	  increase	  73,75.	  The	  activation	  of	  the	  negative	  feedback	  loop	  causes	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macrophage	  hyporesponsiveness	  to	  secondary	  pro-­‐inflammatory	  stimulation,	  also	  known	  as	  
tolerance56,59,61.	  	  
Although	  the	  acute	  impact	  of	  LPS	  on	  macrophages’	  response	  to	  secondary	  LPS	  
stimulation	  has	  been	  extensively	  studied	  57,76,77,	  its	  chronic	  effect	  on	  macrophages	  remains	  
poorly	  explored.	  The	  purpose	  of	  this	  aim	  is	  to	  directly	  investigate	  the	  ability	  of	  macrophages	  to	  
respond	  to	  a	  fresh	  dose	  of	  LPS	  following	  their	  prolonged	  LPS	  exposure.	  We	  hypothesize	  that	  the	  
chronic	  LPS	  stimulation	  of	  macrophages	  will	  decrease	  their	  response	  over	  time	  because	  they	  
may	  develop	  exhaustion	  leading	  to	  their	  hypo	  responsiveness	  to	  environmental	  stimulation.	  We	  
will	  investigate	  macrophages	  responsiveness	  by	  measuring	  TNFa	  protein	  secretion,	  a	  pro-­‐
inflammatory	  cytokine	  78,79.	  Protein	  secretion	  was	  selected	  as	  a	  measurement	  to	  understand	  
cellular	  response	  on	  a	  functional	  level.	  	  
	  
3.2.   Materials	  and	  methods	  
3.2.1.   Experimental	  design	  
Monocytes	  were	  cultured	  under	  different	  treatment	  conditions	  to	  make	  the	  different	  
experimental	  groups	  that	  represent	  chronically	  and	  acutely	  stimulated	  macrophages	  under	  two	  
different	  doses	  of	  LPS	  to	  investigate	  if	  the	  impact	  of	  chronic	  stimulation	  is	  dose	  dependent	  
(Table	  1;	  Figure	  1).	  Based	  on	  our	  standardized	  protocol,	  monocytes	  take	  five	  days	  to	  
differentiate	  macrophages,	  mostly	  marked	  by	  cellular	  adherence	  to	  the	  culture	  dish14.	  Early	  
chronic	  priming-­‐Hi	  and	  Early	  chronic	  priming-­‐Lo	  groups	  are	  chronically	  stimulated	  starting	  at	  
day	  zero	  of	  the	  culture.	  They	  are	  aimed	  to	  model	  the	  systemic	  chronic	  inflammatory	  
stimulation	  of	  monocytes	  to	  investigate	  the	  effect	  of	  monocytes	  pro-­‐inflammatory	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conditioning	  on	  their	  later	  response	  to	  stimulation	  as	  macrophages	  (day	  six).	  Groups	  3	  and	  4	  
are	  controls	  aimed	  to	  model	  the	  acute	  response	  of	  mature	  macrophages.	  Moreover,	  to	  
investigate	  the	  effect	  of	  chronic	  LPS	  stimulation	  on	  mature	  macrophages	  on	  their	  response	  to	  
fresh	  LPS	  stimulation,	  groups	  5	  and	  6,	  which	  are	  late	  chronic	  primed-­‐Hi	  	  and	  late	  chronic	  
primed-­‐Lo	  were	  created	  (Table	  1;	  Figure	  1).	  Unactivated	  macrophages	  (M0)	  exposed	  only	  to	  
media	  containing	  MCSF	  were	  used	  as	  a	  control	  throughout	  the	  experiment.	  Media	  and	  stimuli	  
were	  refreshed	  every	  three	  days.	  
Table	  1.	  	  Experimental	  design	  groups.	  
Experimental	  Group	  	   Treatment	  	  
1)   Early	  chronic	  primingHi	  	  	   Starting	  with	  monocytes	  at	  day	  zero,	  chronically	  
stimulated	  macrophages	  were	  cultured	  for	  7	  days	  in	  
complete	  media	  with	  a	  high	  dose	  of	  LPS	  (100	  ng/ml).	  	  
2)   Early	  chronic	  primingLo	   Starting	  with	  monocytes	  at	  day	  zero,	  chronically	  
stimulated	  macrophages	  were	  cultured	  for	  7	  days	  in	  
complete	  media	  with	  a	  low	  dose	  of	  LPS	  (1	  ng/ml).	  
3)   Acute	  primingHi	   Starting	  at	  day	  6,	  mature	  macrophages	  were	  exposed	  to	  
(100	  ng/ml)	  LPS	  for	  24	  hours.	  	  
4)   Acute	  primingLo	   Starting	  at	  day	  6,	  mature	  macrophages	  were	  exposed	  to	  (1	  
ng/ml)	  LPS	  for	  24	  hours.	  
5)   Late	  chronic	  primingHi	  	  	   Starting	  at	  day	  six,	  mature	  macrophages	  were	  stimulated	  
with	  (100	  ng/ml)	  LPS	  for	  7	  days,	  until	  day	  13.	  
6)   Late	  chronic	  primedLo	   Starting	  at	  day	  six,	  mature	  macrophages	  were	  stimulated	  




Figure	  2.	  Experimental	  design	  timeline	  for	  aim	  one.	  	  The	  experiment	  was	  repeated	  with	  high	  
and	  low	  LPS	  dose.	  
	  
3.2.2.   Cell	  culture-­‐	  Primary	  human	  monocytes	  (purchased	  from	  University	  of	  Pennsylvania	  
Human	  Immunology	  Core,	  Philadelphia,	  PA).	  Cells	  were	  cultured	  in	  at	  37	  C	  and	  5%	  
CO2	  in	  ultralow	  24	  wells	  culture	  plates	  (Corning)	  in	  complete	  media	  (RPMI	  
(Thermofisher),	  %10	  heat-­‐inactivated	  human	  serum	  (	  Sigma	  Aldrich),	  	  1%	  penicillin	  
streptomycin	  (Thermofisher)	  and	  20	  ng/ml	  and	  macrophage	  colony	  stimulating	  
factor	  MCSF	  (Peprotech)	  ).	  The	  seeding	  density	  of	  cells	  was	  approximately	  800	  
thousand	  cells/ml.	  Lipopolysaccharides	  (LPS)	  was	  purchased	  from	  Sigma	  Aldrich	  and	  
used	  to	  stimulate	  pro-­‐inflammatory	  “M1”	  macrophages.	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3.2.3.   Enzyme	  linked	  immunoassay	  -­‐	  	  At	  day	  3,6,7	  and	  13,	  media	  was	  collected,	  
centrifuged	  and	  the	  supernatants	  were	  stored	  at	  -­‐80	  until	  later	  Enzyme	  linked	  
immunoassay	  for	  cellular	  secretion	  of	  TNFa	  (Peprotech).	  To	  count	  the	  total	  cell	  
number	  in	  the	  well,	  adhered	  cells	  were	  scraped	  and	  combined	  with	  the	  centrifuged	  
cell	  pullet	  and	  resuspended	  in	  1	  ml	  media.	  Cells	  were	  counted	  using	  countess	  image	  
analysis	  processer	  and	  live	  cells	  number	  was	  recorded.	  	  
3.2.4.   Statistical	  analysis	  -­‐	  Our	  hypothesis	  was	  tested	  on	  six	  biological	  replicates	  from	  one	  
human	  donor	  using	  One-­‐way	  or	  two-­‐way	  analysis	  of	  variance,	  with	  Tukey’s	  post-­‐hoc	  
multiple	  comparison.	  P	  <	  0.05	  was	  considered	  significant	  for	  all	  analyses.	  Error	  bars	  
in	  all	  figures	  represents	  standard	  error	  of	  mean.	  	  
	  
3.2.   Results	  
	  
To	  confirm	  that	  macrophages	  respond	  to	  acute	  LPS	  stimulation	  by	  increasing	  their	  TNFa	  
secretion,	  macrophages	  were	  differentiated	  from	  monocytes	  by	  culturing	  for	  six	  days	  in	  
complete	  media	  with	  MCSF,	  according	  to	  our	  standard	  protocol.	  At	  day	  six,	  they	  were	  
stimulated	  with	  a	  high	  or	  low	  doses	  of	  LPS	  for	  24	  hours	  and	  their	  culture	  media	  were	  analyzed.	  
Although	  TNFa	  secretion	  was	  not	  different	  between	  groups	  treated	  with	  high	  or	  low	  LPS,	  they	  
were	  both	  higher	  than	  M0	  macrophages	  (Figure	  3).	  	  These	  results	  confirm	  that	  secretion	  of	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TNFa	  is	  a	  good	  indicator	  of	  the	  response	  of	  macrophages	  to	  LPS	  stimulation.	  	  	  	  
	  
	  Figure	  3.	  TNFa	  secretion	  from	  macrophages	  either	  un-­‐activated,	  stimulated	  with	  low	  dose	  of	  
LPS	  (1ng/ml)	  or	  with	  high	  dose	  of	  LPS(100ng/ml).	  Data	  collected	  from	  n=3	  experimental	  






To	  investigate	  the	  effect	  of	  chronic	  LPS	  stimulation	  on	  macrophages’	  TNFa	  secretion,	  
macrophages	  were	  stimulated	  with	  high	  or	  low	  LPS	  doses	  for	  six	  days	  starting	  with	  monocytes	  
at	  day	  zero,	  with	  the	  media	  being	  refreshed	  at	  day	  three.	  TNFa	  secretion	  was	  significantly	  
reduced	  over	  time	  following	  the	  prolonged	  exposure	  to	  either	  high	  or	  low	  doses	  of	  LPS	  
treatment	  (Figure	  4).	  Interestingly,	  by	  day	  six,	  chronically	  stimulated	  macrophages	  by	  high	  or	  




Figure	  4.	  TNFa	  secretion	  overtime	  in	  response	  to	  chronic	  stimulation	  with	  1	  ng/ml	  LPS	  or	  100	  
ng/ml	  LPS.	  Data	  collected	  from	  n=6	  experimental	  replicates,	  one	  biological	  donor.	  Error	  bars	  are	  




	  Furthermore,	  to	  compare	  the	  response	  of	  macrophages	  that	  are	  acutely	  stimulated	  by	  
LPS	  relative	  to	  ones	  that	  has	  been	  already	  exposed	  to	  LPS	  for	  prolonged	  period,	  we	  
simultaneously	  cultured	  M0	  and	  chronically	  stimulated	  macrophages	  using	  high	  or	  low	  LPS	  
doses	  for	  six	  days,	  with	  the	  media	  being	  refreshed	  at	  day	  three.	  By	  day	  six,	  chronically	  
stimulated	  macrophages	  and	  M0	  macrophages	  were	  stimulated	  with	  a	  fresh	  high	  or	  low	  LPS	  
dose.	  The	  collected	  media	  from	  both	  groups	  at	  day	  seven	  were	  analyzed	  for	  their	  TNFa	  
secretion.	  A	  higher	  TNFa	  secretion	  was	  observed	  in	  the	  acutely	  stimulated	  group	  in	  both	  high	  
and	  low	  doses	  of	  LPS	  (Figure	  5;	  Figure	  6).	  These	  data	  suggest	  that	  chronic	  stimulation	  of	  
monocytes	  with	  high	  LPS	  dose	  exhausts	  their	  response	  to	  fresh	  LPS	  stimulation.	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Figure	  5.	  Macrophage	  population	  stimulated	  with	  with	  high	  (100ng/ml)	  dose	  of	  LPS	  for	  chronic	  




Figure	  6.	  Macrophage	  population	  stimulated	  with	  with	  low(1ng/ml)	  dose	  of	  LPS	  for	  chronic	  
versus	  acute	  duration.	  	  
	  
Macrophage	  population	  stimulated	  for	  chronic	  versus	  acute	  duration	  with	  LPS:	  Macrophage	  
population	  stimulated	  with	  with	  high(100ng/ml)	  or	  low	  (1ng/ml)	  dose	  of	  LPS	  for	  chronic	  versus	  
acute	  duration.	  TNFa	  secretion	  from	  macrophage	  population	  stimulated	  with	  high	  or	  low	  LPS	  
for	  seven	  days	  versus	  macrophage	  population	  stimulated	  high	  or	  low	  LPS	  for	  one	  day.	  The	  
media	  was	  refreshed	  24	  hours	  prior	  to	  collection	  in	  all	  groups.	  Data	  collected	  from	  n=3	  
experimental	  replicates,	  one	  biological	  donor.	  Error	  bars	  are	  mean	  +/-­‐	  SEM.	  One	  way	  ANOVA	  
with	  Tukey’s	  post	  hoc.	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Moreover,	  to	  understand	  the	  effect	  of	  chronic	  LPS	  stimulation	  on	  fully	  differentiated	  
macrophages,	  we	  repeated	  the	  above	  experiment	  but	  we	  started	  the	  chronic	  stimulation	  of	  
macrophages	  at	  day	  six	  of	  the	  culture	  when	  the	  cells	  were	  mature	  macrophages	  (M0),	  instead	  
of	  day	  zero	  (monocytes).	  The	  chronic	  LPS	  stimulation	  was	  continued	  for	  seven	  days.	  
Interestingly,	  chronic	  stimulation	  of	  starting	  at	  the	  mature	  macrophage	  (M0)	  stage	  and	  using	  
high	  or	  low	  LPS	  doses,	  lead	  to	  significantly	  less	  TNFa	  secretion	  relative	  to	  acutely	  primed	  group	  
(Figure	  7;	  Figure	  8).	  These	  data	  suggests	  that	  chronically	  stimulating	  mature	  macrophages	  


















Figure	  8.	  Effects	  of	  chronic	  low	  LPS	  stimulation	  on	  TNFa	  secretion	  from	  starting	  at	  the	  mature	  
macrophage	  stage.	  
	  
Effects	  of	  chronic	  high	  LPS	  stimulation	  on	  TNFa	  secretion	  from	  starting	  at	  the	  mature	  
macrophage	  stage:	  Macrophages	  treated	  with	  high	  or	  low	  LPS	  for	  seven	  days	  starting	  	  at	  day	  six	  
from	  the	  start	  of	  the	  culture,	  until	  day	  13.	  M0	  represents	  an	  un-­‐activated	  macrophage	  group	  
that	  remained	  in	  the	  culture	  for	  13	  days.	  Data	  collected	  from	  n=3	  experimental	  replicates	  from	  









3.3.   Discussion	  
	  
Acute	  inflammation	  has	  a	  plethora	  of	  beneficial	  effects	  on	  tissue	  regeneration.	  Beside	  
its	  known	  role	  in	  clearing	  debris	  and	  fighting	  infections,	  it	  is	  an	  important	  initiator	  of	  
angiogenesis15	  and	  cellular	  proliferation16.	  For	  example,	  it	  has	  been	  shown	  in	  vivo	  that	  early	  and	  
high	  expression	  of	  LPS	  receptor	  called	  toll	  like	  receptor	  2	  (TLR2),	  expressed	  on	  M1	  
macrophages,	  is	  associated	  with	  improved	  healing	  outcomes	  due	  to	  enhancing	  cellular	  
proliferation	  and	  migration80.	  Similarly,	  it	  has	  been	  suggested	  that	  acute	  LPS	  stimulation	  of	  
wounds	  facilitate	  faster	  healing	  by	  accelerating	  inflammatory	  resolution,	  increasing	  
macrophage	  infiltration	  further	  enhancing	  angiogenesis	  and	  cellular	  proliferation	  by	  
upregulating	  TGFB	  and	  VEGF	  81.	  Macrophages	  are	  the	  major	  players	  in	  the	  inflammatory	  
response4.	  Therefore,	  understanding	  the	  impact	  of	  different	  environmental	  conditions	  on	  their	  
behavior	  is	  essential	  to	  understand	  potential	  reasons	  for	  the	  changes	  in	  their	  behavior	  in	  
pathological	  conditions,	  ultimately	  to	  inform	  new	  treatments.	  	  
Patients	  with	  chronic	  inflammatory	  diseases	  have	  been	  shown	  to	  also	  possess	  a	  slightly	  
elevated	  levels	  of	  LPS	  	  that	  are	  also	  linked	  to	  high	  cholesterol	  and	  sugar	  diet,	  chronic	  smoking	  or	  
drinking	  ,	  which	  collectively	  are	  associated	  with	  increasing	  the	  risk	  of	  developing	  complications	  
29,42,74,82-­‐84.	  Therefore,	  it	  is	  important	  to	  understand	  how	  chronic	  exposure	  to	  LPS	  impact	  
macrophages,	  which	  are	  essential	  players	  in	  tissue	  regeneration5.	  
It	  is	  established	  that	  high	  and	  acute	  dosage	  of	  LPS	  stimulation	  cause	  macrophages	  to	  
mount	  an	  acute,	  resolving	  inflammation	  and	  tolerant	  behavior	  to	  subsequent	  stimulation	  which	  
recover	  with	  increasing	  their	  resting	  phase74,85.	  While	  the	  impact	  of	  primary	  and	  acute	  LPS	  
stimulation	  on	  macrophage	  tolerance	  against	  a	  secondary	  LPS	  stimulation	  has	  been	  extensively	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studied,	  the	  direct	  effect	  of	  chronic	  and	  continuous	  exposure	  of	  macrophage	  to	  LPS	  in	  the	  
context	  of	  wound	  healing	  remains	  poorly	  understood.	  It	  has	  been	  highlighted	  that	  aging	  causes	  
a	  general	  macrophages	  exhaustion	  due	  to	  continuous	  immune	  stimulation46.	  However,	  how	  
macrophages	  exhaustion	  caused	  by	  chronic	  stimulation	  impact	  macrophages	  wound	  healing	  
functions,	  remains	  poorly	  understood.	  We	  hypothesized	  that	  chronic	  LPS	  stimulation	  of	  
macrophages	  will	  exhaust	  macrophages	  pro-­‐inflammatory	  activation.	  Our	  findings	  suggested	  
that	  monocytes	  and	  macrophages	  chronically	  stimulated	  with	  LPS	  exhausted	  their	  TNFa	  
secretion	  in	  response	  to	  further	  LPS	  stimulation	  (Figure	  5-­‐	  8).	  Our	  findings	  may	  have	  a	  major	  
physiological	  relevance	  as	  it	  was	  recently	  shown	  that	  mature	  tissue	  macrophages	  in	  addition	  to	  
circulating	  monocytes	  are	  essential	  initial	  responders	  in	  the	  wound	  healing	  response86.	  Future	  
studies	  are	  needed	  to	  further	  understand	  the	  mechanisms	  of	  macrophage	  exhaustion.	  
We	  speculate	  that	  macrophage	  hyporesponsiveness	  to	  LPS	  may	  render	  cells	  unable	  to	  
mount	  a	  proper	  acute	  inflammatory	  response	  to	  injury,	  leading	  to	  impaired/delayed	  wound	  
healing.	  We	  think	  that	  chronic	  LPS	  stimulation	  may	  activate	  negative	  regulatory	  pathways	  
making	  the	  cells	  hyporesponsive	  to	  other	  pro-­‐inflammatory	  stimulation.	  It	  has	  been	  previously	  
shown	  that	  NFKB	  signaling	  is	  tightly	  regulated	  by	  a	  negative	  feedback	  loop	  that	  prevents	  
excessive	  inflammation	  87.	  Classical	  inflammatory	  activation	  of	  NFKB	  is	  mediated	  via	  p65	  and	  
p50	  heterodimer87.	  P50	  homodimer	  has	  been	  highlighted	  as	  an	  important	  repressor	  of	  the	  
inflammatory	  response	  87.	  NFKB	  is	  repressed	  when	  p50/p50	  homodimer	  binds	  to	  the	  DNA	  
because	  p50,	  unlike	  p65	  lacks	  a	  transtrascriptional	  domain87.	  Thus	  far,	  little	  is	  known	  about	  the	  
regulation	  of	  p50/p50	  binding	  87.	  P50/P50	  homodimer	  binding	  has	  been	  suggested	  to	  be	  a	  
mechanism	  through	  which	  IL-­‐10	  promotes	  its	  anti-­‐inflammatory	  activities.	  In	  acute	  macrophage	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tolerance,	  p50/p50	  homodimer	  repressive	  binding	  has	  been	  shown	  to	  play	  a	  role	  in	  
macrophage	  hypo-­‐responsiveness	  to	  LPS	  88.	  Future	  study	  needs	  to	  confirm	  if	  p50/p50	  
homodimer	  repressive	  binding	  was	  mediating	  macrophage	  chronic	  hyporesponsiveness	  and	  if	  
this	  mechanism	  was	  IL10	  or	  IL10	  dependent.	  	  
	  
4.   Aim	  2.	  The	  impact	  of	  chronic	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐M2	  switching	  
	  
4.2.   Background	  
	  
The	  M1-­‐to-­‐M2	  shift	  in	  macrophages	  population	  is	  essential	  for	  normal	  wound	  healing	  
and	  it	  has	  been	  shown	  to	  be	  impaired	  in	  chronic	  wounds	  18,25.	  Evidence	  suggests	  that	  
macrophages	  in	  type	  2	  diabetes	  are	  hyporesponsive	  to	  anti-­‐inflammatory	  stimulation.	  For	  
example,	  Barry	  et	  al.	  89	  	  showed	  that	  macrophages	  cultured	  in	  hyperglycemic	  conditions	  were	  
hyporesponsive	  	  to	  interleukin	  10	  (IL10),	  an	  anti-­‐inflammatory	  stimulation,	  which	  was	  not	  
explained	  by	  a	  change	  in	  IL10	  receptor89.	  	  
Additionally,	  O’Connor	  et	  al.90	  showed	  impaired	  IL4	  signaling	  in	  in	  macrophages	  isolated	  
from	  a	  diabetic	  mouse	  model.	  The	  impaired	  signaling	  was	  mediated	  by	  increased	  expression	  of	  
suppressor	  of	  cytokine	  signaling	  3	  (SOSC3)	  90.	  Since	  we	  previously	  mentioned	  that	  LPS	  levels	  are	  
increased	  in	  chronic	  inflammatory	  diseases,	  and	  the	  prolonged	  LPS	  exposure	  also	  causes	  SOSC3	  
activation	  in	  macrophages	  91,	  we	  expect	  that	  LPS	  chronic	  exposure	  will	  impair	  macrophages	  
response	  to	  IL4/IL13.	  	  
Therefore,	  the	  purpose	  of	  this	  aim	  is	  to	  examine	  the	  impact	  of	  chronic	  LPS	  stimulation	  
on	  macrophages	  M1-­‐to-­‐M2	  switching,	  by	  investigating	  their	  PDGBB,	  CCL18	  (M2	  markers)14	  and	  
TNFa	  protein	  secretion	  (M1	  marker)	  ,	  relative	  to	  M0-­‐to-­‐M2	  switching	  and	  acute	  M1-­‐to-­‐M2	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switching	  controls.	  
4.3.   Materials	  and	  methods	  
	  
4.3.3.   	  Experimental	  design-­‐	  Groups	  1,2,3,	  and	  4	  from	  Aim	  1	  (Table	  1)	  were	  used	  to	  examine	  
the	  impact	  of	  LPS	  chronic	  stimulation	  starting	  at	  the	  monocyte	  stage	  (modeling	  the	  
systemic	  LPS	  effect)	  on	  the	  capacity	  of	  macrophages	  to	  respond	  to	  IL4/IL13	  by	  secreting	  
M2-­‐associated	  proteins,	  especially	  PDGFBB	  and	  CCL18.	  At	  day	  7	  of	  the	  culture,	  mature	  
macrophages	  were	  switched	  to	  complete	  media	  containing	  40	  ng/ml	  IL4	  and	  20	  ng/ml	  
IL13	  cytokines	  for	  24	  hours.	  IL13/IL4	  cytokines	  and	  fresh	  media	  volume	  were	  decided	  
based	  on	  cell	  number	  at	  day	  seven	  to	  ensure	  a	  ratio	  of	  1	  million	  cells	  per	  ml.	  
Unactivated	  macrophages	  (M0)	  exposed	  to	  media	  containing	  MCSF	  and	  directly	  
stimulated	  by	  IL4/IL13	  at	  day	  seven	  were	  used	  as	  controls.	  For	  all	  groups,	  the	  media	  was	  
refreshed	  every	  three	  days	  and	  at	  day	  seven.	  
 
	  
4.2.2.	  Cell	  culture-­‐	  	  Primary	  human	  monocytes	  (purchased	  from	  University	  of	  
Pennsylvania	  Human	  Immunology	  Core,	  Philadelphia,	  PA).	  Cells	  were	  cultured	  in	  at	  37	  C	  
and	  5%	  CO2	  in	  ultralow	  24	  wells	  culture	  plates	  (Corning)	  in	  complete	  media	  (RPMI	  
(Thermofisher),	  %10	  heat-­‐inactivated	  human	  serum	  (	  Sigma	  Aldrich),	  	  1%	  penicillin	  
streptomycin	  (Thermofisher)	  and	  20	  ng/ml	  and	  macrophage	  colony	  stimulating	  factor	  
MCSF	  (Peprotech)	  ).	  The	  seeding	  density	  of	  cells	  was	  approximately	  800	  thousand	  
cells/ml.	  Lipopolysaccharides	  (LPS)	  was	  purchased	  from	  Sigma	  Aldrich	  and	  used	  to	  
stimulate	  pro-­‐inflammatory	  “M1”	  macrophages.	  Interleukin	  4	  and	  interleukin	  13	  (IL4	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/IL13)	  cytokines	  were	  purchased	  from	  Peprotech	  and	  used	  to	  stimulate	  the	  anti-­‐
inflammatory	  “M2”	  response.	  
4.2.3.	  	  Enzyme	  linked	  immunoassay-­‐	  	  	  	  At	  day	  7	  (M1)	  and	  8	  (M2),	  media	  was	  collected,	  
centrifuged	  and	  the	  supernatants	  were	  stored	  at	  -­‐80	  until	  later	  Enzyme	  linked	  
immunoassay	  for	  cellular	  secretion	  of	  TNFa,	  PDGFBB	  (Peprotech)	  and	  CCL18	  (PARC,	  R&D	  
systems).	  Additionally,	  at	  day	  7	  and	  8,	  cells	  were	  scraped	  gently	  to	  count	  their	  number	  
using	  a	  countess	  automated	  cell	  counter	  (Invitrogen).	  To	  count	  the	  total	  cell	  number	  in	  
the	  well,	  adhered	  cells	  were	  scraped	  and	  combined	  with	  the	  centrifuged	  cell	  pullet	  and	  
resuspended	  in	  1	  ml	  media.	  Cells	  were	  counted	  using	  countess	  image	  analysis	  processer	  
and	  live	  cells	  number	  was	  recorded.	  
4.2.4.	  	  Statistical	  analysis-­‐	  	  please	  refer	  to	  section	  3.2.4.	  
	  
	  
4.3.   	  	  Results	  
	  
To	  investigate	  M2	  repolarization	  capacity	  of	  acutely	  stimulated	  macrophages	  using	  high	  
or	  low	  LPS	  doses,	  different	  macrophage	  groups	  were	  stimulated	  with	  IL13/IL4	  cytokines	  for	  24	  
hours.	  Their	  M1-­‐to-­‐M2	  switching	  capacity	  was	  measured	  by	  their	  increased	  secretion	  of	  CCL18,	  
PDGFBB	  (M2	  markers)	  and	  decreased	  secretion	  of	  TNFa	  (M1	  marker).	  To	  test	  the	  impact	  of	  
chronic	  stimulation	  of	  LPS	  on	  macrophages	  M1-­‐to-­‐M2	  switching.	  Macrophages	  were	  chronically	  
activated	  using	  high	  or	  low	  LPS	  doses,	  until	  day	  7.	  All	  groups	  were	  then	  switched	  to	  (IL13/IL4)	  
for	  24	  hours,	  until	  day	  8.	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On	  a	  population	  level,	  chronic	  stimulation	  using	  high	  LPS	  did	  not	  impact	  macrophages	  
increase	  in	  CCL18	  secretion	  post	  IL13/IL4	  treatment	  (Figure	  9	  A).	  However,	  normalizing	  to	  live	  
cell	  number	  revealed	  that	  CCL18	  secretion	  only	  significantly	  increased	  post	  IL13/IL4	  treatment	  
in	  chronically	  primed	  groups	  (Figure	  9	  C).	  	  Fold	  change	  increase	  in	  CCL18	  secretion	  was	  the	  
highest	  in	  chronically	  primed	  group	  (Figure	  9	  D).	  Acute	  stimulation	  with	  high	  LPS	  reduced	  
macrophages	  response	  to	  IL13/IL4	  as	  shown	  by	  their	  lower	  CCL18	  secretion	  relative	  to	  M0-­‐to-­‐
M2	  control	  (Figure	  9	  D).	  
PDGFBB	  protein	  increased	  secretion	  in	  response	  to	  IL13/IL4	  was	  impaired	  on	  a	  
population	  level	  in	  chronically	  stimulated	  macrophages	  (Figure	  10	  A).	  However,	  they	  increased	  
their	  PDGFBB	  secretion	  on	  a	  single	  cell	  level	  (Figure	  10	  C).	  Fold	  change	  increase	  in	  PDGFBB	  
secretion	  was	  the	  highest	  in	  chronically	  primed	  group	  (Figure	  10	  D).	  Acute	  stimulation	  with	  high	  
LPS	  reduced	  macrophages	  response	  to	  IL13/IL4	  as	  shown	  by	  their	  lower	  PDGFBB	  secretion	  
relative	  to	  M0-­‐to-­‐M2	  control	  (Figure	  10	  D).	  
TNFa	  secretion	  was	  not	  impacted	  post	  IL13/4	  stimulation	  on	  a	  populations	  and	  single	  
cell	  level	  in	  chronically	  stimulated	  groups	  and	  reduced	  in	  acutely	  stimulated	  groups	  (Figure	  11).	  	  	  
Interestingly,	  at	  day	  7	  (before	  IL4/IL13	  stimulation),	  chronically	  stimulated	  macrophages	  
with	  high	  LPS	  had	  a	  higher	  CCL18	  secretion	  relative	  to	  acutely	  stimulated	  group	  (	  Figure	  13	  C).	  
These	  results	  suggest	  that	  chronic	  high	  LPS	  stimulation	  rendered	  cells	  more	  responsive	  to	  
IL13/IL4	  as	  it	  was	  measured	  by	  their	  higher	  PDGFBB	  and	  CCL18	  secretion	  relative	  to	  M0-­‐to-­‐








Figure	  9.	  CCL18	  secretion:	  The	  impact	  of	  chronic	  high	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐
M2	  switch.	  Interaction	  is	  not	  significant	  (p=0.2974)  
	  
Figure	  10.	  PDGFBB	  secretion:	  The	  impact	  of	  chronic	  high	  LPS	  stimulation	  on	  macrophages	  M1-­‐
to-­‐M2	  switch.	  Interaction	  was	  significant	  (p<0.0001)  
	  
Figure11.	  TNFa	  secretion:	  The	  impact	  of	  chronic	  high	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐
M2	  switch.	  Interaction	  was	  significant	  (p=0.0015)  
  
  
M1-­‐to-­‐M2	  switch	  from	  chronically	  stimulated	  macrophages	  with	  high	  LPS	  :Macrophages	  
activated	  by	  100	  ng/ml	  LPS	  for	  seven	  days	  versus	  for	  one	  day,	  were	  switched	  to	  IL13/IL4	  
containing	  media	  for	  24	  hours,	  until	  day	  8.	  M0	  control	  switched	  to	  IL13/4	  was	  used	  as	  a	  control.	  
A)	  Protein	  was	  measured	  before	  (day	  7)	  and	  after	  IL4/IL13	  stimulation	  (day	  8).	  B)	  Live	  cell	  
number	  in	  different	  treatment	  groups	  using	  trypan	  blue	  exclusion	  assay	  before	  and	  after	  
IL4/IL13	  stimulation.	  C)	  Protein	  secretion	  normalized	  to	  the	  average	  of	  live	  cell	  number.	  D)	  Fold	  
change	  of	  protein	  secretion.	  The	  media	  was	  refreshed	  24	  hours	  prior	  to	  collection	  in	  all	  groups.	  
PDGFBB	  Data	  collected	  from	  n=6	  experimental	  replicates.	  CCL18	  and	  TNFa	  data	  were	  collacted	  
from	  n=3	  experimental	  replicates.	  All	  data	  came	  from	  one	  biological	  replicates.	  Error	  bars	  are	  




Chronic	  stimulation	  using	  low	  LPS	  did	  not	  impact	  macrophages	  increase	  in	  CCL18	  
secretion	  (Figure	  12).	  Fold	  change	  over	  “before	  IL13/IL4	  treatment”	  revealed	  that	  chronic	  
stimulation	  made	  macrophages	  secrete	  the	  highest	  CCL18	  in	  response	  to	  IL13/IL4	  (Figure	  12	  D).	  
PDGFBB	  secretion	  did	  not	  increase	  in	  chronically	  primed	  group	  post	  IL13/IL4	  treatment	  (figure	  
13).	  Also,	  all	  groups	  decreased	  their	  TNFa	  secretion	  post	  IL13/4	  stimulation	  (Figure	  14	  ).	  
Interestingly,	  at	  day	  7	  (before	  IL4/IL13	  stimulation),	  chronically	  stimulated	  macrophages	  with	  
low	  LPS	  had	  a	  higher	  M2	  associated	  proteins	  secretion	  relative	  to	  acutely	  stimulated	  group.	  
These	  results	  suggest	  that	  chronic	  low	  LPS	  stimulation	  rendered	  cells	  more	  responsive	  to	  
IL13/IL4	  in	  terms	  of	  their	  CCL18	  secretion,	  not	  PDGFBB	  secretion,	  relative	  to	  M0-­‐to-­‐M2	  
control.	  However,	  acute	  stimulation	  with	  low	  LPS	  did	  not	  impact	  macrophages	  response	  to	  





Figure12.	  CCL18	  secretion:	  The	  impact	  of	  chronic	  low	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐




Figure13.	  PDGFBB	  secretion:	  The	  impact	  of	  chronic	  low	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐
M2	  switch.	  Interaction	  was	  not	  significant	  (p=0.0712)  
Figure14.	  TNFa	  secretion:	  The	  impact	  of	  chronic	  low	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐M2	  
switch.	  Interaction	  was	  significant	  (p<0.0001)	  
M1-­‐to-­‐M2	  switch	  from	  chronically	  stimulated	  macrophages	  with	  high	  LPS:	  The	  impact	  of	  
chronic	  low	  LPS	  stimulation	  on	  macrophages	  M1-­‐to-­‐M2	  switch.	  Macrophages	  activated	  by	  1	  
ng/ml	  LPS	  for	  seven	  days	  versus	  for	  one	  day,	  were	  switched	  to	  IL13/IL4	  containing	  media	  for	  24	  
hours,	  until	  day	  8.	  M0	  control	  switched	  to	  IL13/4	  was	  used	  as	  a	  control.	  A)	  Protein	  was	  
measured	  before	  (day	  7)	  and	  after	  IL4/IL13	  stimulation	  (day	  8).	  B)	  Live	  cell	  number	  in	  different	  
treatment	  groups	  using	  trypan	  blue	  exclusion	  assay	  before	  and	  after	  IL4/IL13	  stimulation.	  C)	  
Protein	  secretion	  normalized	  to	  cell	  number.	  The	  media	  was	  refreshed	  24	  hours	  prior	  to	  
collection	  in	  all	  groups.	  PDGFBB	  Data	  collected	  from	  n=3	  experimental	  replicates.	  CCL18	  and	  
TNFa	  data	  were	  collected	  from	  n=3	  experimental	  replicates.	  All	  data	  came	  from	  one	  biological	  
replicates.	  Error	  bars	  are	  mean	  +/-­‐	  SEM.	  Two	  way	  or	  one	  way	  ANOVA	  with	  Tukey’s	  post	  hoc	  was	  









Table	  2.	  	  Summary	  of	  results	  from	  aim	  2	  reported	  as	  it	  compares	  to	  before	  IL13/IL4	  treatment	  
	  
Condition	   Population	   Single	  cell	  
Chronic	  high	  LPS	  	  	   CCL18_	  increased	  
PDGFBB_	  not	  impacted	  
CCL18_	  increased	  
PDGFBB_	  increased	  
Chronic	  low	  LPS	   CCL18_	  increased	  
PDGFBB_	  reduced	  
CCL18_	  increased	  
PDGFBB_	  not	  impacted	  
	  









4.4.   Discussion	  
 
Although	  acute	  inflammation	  is	  critical	  for	  successful	  wound	  healing,	  chronic	  
inflammation	  has	  detrimental	  effects25.Many	  research	  focus	  of	  promoting	  the	  M2	  phenotype	  to	  
promote	  healing	  of	  chronic	  inflammatory	  conditions92.	  Due	  to	  the	  important	  functions	  of	  an	  
acute	  M1	  activation	  in	  wound	  healing,	  unlike	  chronic	  M1,	  we	  investigated	  if	  an	  acute	  versus	  
chronic	  M1	  activation	  impact	  their	  M2	  activation.	  	  
Here	  we	  showed	  that	  acute	  LPS	  stimulation	  with	  low	  (1	  ng/ml)	  LPS	  dose,	  not	  high	  dose,	  
facilitated	  an	  efficient	  cellular	  repolarization	  that	  is	  not	  different	  from	  direct	  polarization	  from	  
M0	  to	  M2	  macrophage	  (Figure	  10;	  Figure	  11;	  Figure	  12),	  suggesting	  that	  acute	  inflammatory	  
phase	  does	  not	  reduce	  macrophages	  M1-­‐to-­‐M2	  switching	  capacity.	  Indeed,	  Ostuni	  et	  al.93	  
showed	  LPS	  impact	  macrophages	  epigenetic	  memory	  to	  facilitate	  modifications	  in	  their	  
responsive	  capacity.	  Here,	  we	  found	  that	  high	  (100ng/ml)	  LPS	  stimulation	  impaired	  the	  
efficiency	  of	  macrophages	  to	  secrete	  M2	  associated	  proteins	  upon	  stimulation	  with	  IL13/IL4	  
(Figure	  10;	  Figure	  11).	  
Interestingly,	  chronic	  high	  LPS	  stimulation	  rendered	  cells	  more	  responsive	  to	  IL13/IL4	  as	  
it	  was	  measured	  by	  their	  higher	  PDGFBB	  and	  CCL18	  secretion	  relative	  to	  M0-­‐to-­‐M2	  control.	  
However,	  acute	  stimulation	  with	  high	  LPS	  rendered	  macrophages	  less	  responsive	  to	  IL13/IL4	  as	  
shown	  by	  their	  lower	  CCL18	  and	  PDGFBB	  secretion	  relative	  to	  M0-­‐to-­‐M2	  control.	  On	  the	  other	  
hand,	  chronic	  low	  LPS	  stimulation	  rendered	  cells	  more	  responsive	  to	  IL13/IL4	  in	  terms	  of	  their	  
CCL18	  secretion,	  not	  PDGFBB	  secretion,	  relative	  to	  M0-­‐to-­‐M2	  control.	  However,	  acute	  
42  
stimulation	  with	  low	  LPS	  did	  not	  impact	  macrophages	  response	  to	  IL13/IL4	  as	  shown	  by	  their	  
similar	  CCL18	  and	  PDGFBB	  secretion	  relative	  to	  M0-­‐to-­‐M2	  control.	  	  
In	  diabetic	  ulcers,	  non-­‐healing	  patients,	  expressed	  a	  lower	  initial	  pro-­‐inflammatory	  
markers	  relative	  to	  patients	  that	  healed	  25.	  Some	  evidence	  suggest	  that	  we	  need	  high	  level	  for	  
initially	  acute	  inflammation	  to	  enable	  a	  better	  inflammatory	  resolution	  25,94,95	  .	  Many	  studies	  
that	  investigated	  macrophage	  tolerance	  suggests	  that	  stimulating	  macrophages	  with	  two	  high	  
doses	  of	  LPS	  separated	  by	  a	  resting	  phase	  to	  induce	  the	  tolerance	  response	  promote	  their	  
capacity	  to	  activate	  their	  M2	  associated	  response	  45,96,97	  by	  capitalizing	  on	  the	  activation	  of	  the	  
opposing	  inflammatory	  and	  anti-­‐inflammatory	  roles	  of	  NFKB	  45,75.	  Interestingly,	  we	  observed	  
that	  chronically	  stimulated	  macrophages	  lead	  to	  a	  slightly	  higher	  M2	  associated	  proteins’	  
secretion	  relative	  to	  acutely	  stimulated	  groups.	  Thus,	  we	  speculate	  that	  the	  impaired	  pro-­‐
inflammatory	  activation	  in	  the	  initial	  phases	  of	  chronic	  wounds	  may	  be	  due	  to	  the	  impairment	  
of	  the	  rapid	  M1	  associated	  response	  to	  injury(shown	  in	  aim	  1	  data),	  along	  with	  skewing	  their	  
activation	  to	  M2	  like	  phenotype	  by	  their	  hyper-­‐response	  to	  M2	  stimulations,	  not	  M1	  
stimulation.	  Collectively,	  this	  disrupted	  behavior	  may	  lead	  macrophages	  to	  mount	  a	  
dysfunctional	  initial	  inflammatory	  response	  and	  	  slow	  the	  overall	  propagation	  of	  the	  healing	  
response	  due	  to	  the	  lack	  of	  temporal	  control	  over	  their	  ordered	  phenotypic	  activation	  and	  M1-­‐
to-­‐M2	  switch.	  
In	  conclusion,	  our	  findings	  suggest	  that	  although	  chronic	  LPS	  stimulation	  impaired	  
macrophages	  response	  to	  further	  LPS	  stimulation,	  it	  did	  enhance	  their	  response	  to	  IL13/4	  
possibly	  because	  their	  exhaustion	  was	  limited	  to	  their	  pro-­‐inflammatory	  pathway	  but	  not	  in	  
other	  pathways.	  However,	  we	  think	  that	  the	  observed	  hyper-­‐response	  of	  chronically	  stimulated	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groups	  to	  IL13/IL14	  could	  be	  partially	  mediated	  by	  their	  lack	  of	  ability	  to	  proliferate	  in	  response	  
to	  IL13/IL4,	  dedicating	  more	  energy	  to	  synthesizing	  and	  secreting	  M2	  proteins,	  unlike	  acute	  M1.	  
Acute	  M1	  was	  probably	  more	  or	  equally	  responsive	  to	  IL13/IL4	  but	  by	  means	  of	  cellular	  
proliferation	  and	  protein	  secretion,	  thus,	  secreting	  less	  proteins	  per	  cell	  because	  they	  are	  also	  
investing	  their	  energy	  in	  proliferation,	  unlike	  chronic	  M1.	  	  
Future	  studies	  needs	  to	  further	  investigate	  and	  support	  this	  proposed	  hypothesis	  for	  
impaired	  healing.	  Additionally,	  understanding	  the	  different	  proliferation	  capacities	  of	  chronic	  
versus	  acute	  M1s	  in	  response	  to	  IL13/IL4	  cytokines	  could	  highlight	  the	  need	  to	  rescue	  the	  
proliferative	  capacity	  of	  macrophages	  in	  chronic	  wound	  prior	  to	  delivering	  M2	  promoting	  
cytokine	  therapy.	  
	  
5.   Aim	  3.	  The	  impact	  of	  using	  interferon	  gamma	  treatment	  to	  restore	  the	  responsiveness	  of	  
exhausted	  macrophages	  
5.3.   Background	  
Recent	  	  evidence	  suggests	  that	  the	  initial	  inflammatory	  phase	  of	  chronic	  inflammatory	  
conditions	  is	  impaired25,94.	  We	  suggested	  that	  the	  chronic	  LPS	  increase	  in	  patients	  with	  chronic	  
diseases	  cause	  macrophages	  exhaustion,	  a	  phenomenon	  that	  reduces	  macrophages	  
responsiveness	  to	  environmental	  stimuli,	  like	  fresh	  LPS	  signals.	  Some	  studies	  suggest	  that	  
rescuing	  the	  initial	  inflammatory	  phase	  may	  jump	  start	  the	  wound	  healing	  process94.	  For	  
example,	  in	  a	  diabetic	  mouse	  model	  of	  impaired	  wound	  healing,	  using	  IL1B	  	  inflammatory	  
stimuli	  to	  rescue	  the	  defective	  macrophage	  activation	  improved	  wound	  healing98.	  	  
It	  has	  been	  recently	  showed	  that	  IL10	  signaling	  is	  essential	  for	  the	  maintenance	  of	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exhausted	  macrophage	  phenotype	  which	  was	  imperative	  for	  the	  development	  of	  pathological	  
angiogenesis	  in	  chronic	  eye	  disease52.	  IFNg’s	  ability	  to	  inhibit	  IL10	  and	  partially	  restore	  
macrophages	  functions	  in	  cases	  of	  tolerance63,	  may	  enable	  it	  from	  being	  a	  promising	  candidate	  
to	  restore	  the	  responsiveness	  of	  exhausted	  macrophages	  to	  LPS	  since	  macrophage	  exhausted	  
response	  is	  similar	  to	  its	  tolerant	  response.	  	  	  
Additionally,	  macrophage	  tolerance	  due	  to	  acute	  high	  LPS	  stimulation	  has	  been	  shown	  
to	  cause	  metabolic	  paralysis	  characterized	  by	  decreased	  oxygen	  consumption,	  inability	  to	  
increase	  glycolysis	  and	  less	  transport	  of	  fatty	  acid61.	  Collectively,	  leading	  macrophages	  to	  
reduce	  their	  cytokine	  producing	  capacity61.	  Since	  macrophage	  tolerance	  is	  mediated	  by	  a	  
negative	  feedback	  loop,	  it	  has	  been	  indicated	  that	  interferon	  gamma	  partially	  inhibits	  the	  
negative	  feedback	  loop	  and	  rescue	  macrophages59,60.	  	  IFNg	  treatment,	  partially	  restored	  energy	  
metabolism	  and	  cytokine	  production	  capability	  in	  tolerant	  macrophgaes61.	  	  Additionally,	  IFNg	  
treatment	  has	  been	  shown	  to	  rescue	  macrophages	  capacity	  to	  phagocytose	  dead	  cells	  in	  
chronic	  granulomatous62.	  	  
We	  hypothesized	  that	  treating	  exhausted	  macrophages	  with	  IFNg	  may	  restore	  its	  
responsiveness,	  similar	  to	  its	  effect	  of	  tolerant	  macrophages.	  The	  purpose	  of	  this	  aim	  is	  to	  
investigate	  the	  capacity	  of	  IFNg	  cytokine	  to	  restore	  the	  response	  of	  exhausted	  macrophages	  to	  
LPS,	  and	  to	  investigate	  how	  will	  IFNg	  pretreatment	  impact	  macrophages	  subsequent	  response	  
to	  IL13/IL4	  cytokines	  by	  analyzing	  their	  secretion	  of	  TNFa,	  PDGFBB	  and	  CCL18	  proteins.	  
5.4.   Materials	  and	  method	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5.4.1.   Experimental	  design	  
Groups	  1,2,3,and	  4	  from	  aim	  1	  (Table	  1)	  were	  used	  to	  examine	  the	  impact	  of	  adding	  100	  
ng/ml	  IFNg	  treatment	  at	  day	  six	  of	  the	  culture	  to	  the	  chronically	  stimulated	  groups	  on	  their	  
capacity	  to	  respond	  to	  LPS.	  To	  examine	  if	  IFNg	  pre-­‐treatment	  impact	  its	  later	  response	  to	  
IL13/4,	  at	  day	  7,	  macrophages	  were	  switched	  to	  complete	  media	  containing	  40	  ng/ml	  IL4	  and	  
20	  ng/ml	  IL13	  cytokines	  for	  24	  hours	  (Figure	  12).	  IL13/IL4	  cytokines	  and	  fresh	  media	  volume	  
were	  decided	  based	  on	  cell	  number	  at	  day	  seven	  to	  ensure	  a	  ratio	  of	  1	  million	  cells	  per	  ml.	  M0	  
exposed	  to	  media	  containing	  MCSF	  only,	  M0	  directly	  stimulated	  by	  IL4/IL13	  and	  M0	  stimulated	  
by	  IFNg	  only	  for	  24	  hours	  prior	  to	  their	  Il13/IL4	  treatment	  were	  used	  as	  controls.	  For	  all	  groups,	  




Figure	  15.	  Aim	  three	  experimental	  design	  timeline.	  The	  study	  was	  repeated	  using	  high	  and	  low	  
LPS	  dose.	  
	  
5.4.2.   Cell	  culture	  -­‐	  Primary	  human	  monocytes	  (purchased	  from	  University	  of	  Pennsylvania	  
Human	  Immunology	  Core,	  Philadelphia,	  PA).	  Cells	  were	  cultured	  in	  at	  37	  C	  and	  5%	  CO2	  
in	  ultralow	  24	  wells	  culture	  plates	  (Corning)	  in	  complete	  media	  (RPMI	  (Thermofisher),	  
%10	  heat-­‐inactivated	  human	  serum	  (	  Sigma	  Aldrich),	  	  1%	  penicillin	  streptomycin	  
(Thermofisher)	  and	  20	  ng/ml	  and	  macrophage	  colony	  stimulating	  factor	  MCSF	  
(Peprotech)	  ).	  The	  seeding	  density	  of	  cells	  was	  approximately	  800	  thousand	  cells/ml.	  
Lipopolysaccharides	  (LPS)	  was	  purchased	  from	  Sigma	  Aldrich.	  Interleukin	  4	  and	  
interleukin	  13	  (IL4	  /IL13)	  and	  IFNg	  cytokines	  were	  purchased	  from	  Peprotech.	  
5.4.3.   Enzyme	  linked	  immunoassay	  -­‐	  At	  day	  7(M1)	  and	  8(M2),	  media	  was	  collected,	  
centrifuged	  and	  the	  supernatants	  were	  stored	  at	  -­‐80	  until	  later	  Enzyme	  linked	  
immunoassay	  for	  cellular	  secretion	  of	  TNFa,	  PDGFBB	  and	  CCL18.	  Additionally,	  cells	  were	  
scraped	  gently	  to	  count	  their	  number	  using	  a	  countess	  automated	  cell	  counter	  
(Invitrogen).	  To	  count	  the	  total	  cell	  number	  in	  the	  well,	  adhered	  cells	  were	  scraped	  and	  
combined	  with	  the	  centrifuged	  cell	  pullet	  and	  resuspended	  in	  1	  ml	  media.	  Cells	  were	  
counted	  using	  countess	  image	  analysis	  processer	  and	  live	  cells	  number	  was	  recorded.	  
5.4.4.   Statistical	  analysis	  –	  refer	  to	  section	  3.2.4.	  	  
5.5.   Results	  
Adding	  an	  additional	  dose	  of	  IFNg	  with	  fresh	  LPS	  treatment	  did	  not	  increase	  TNFa	  
secretion	  in	  any	  of	  the	  chronically	  or	  acutely	  LPS	  stimulated	  macrophage	  groups	  (Figure	  16;	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Figure	  17).	  These	  results	  indicate	  that	  IFNg	  dis	  not	  rescue	  the	  hyporesponsiveness	  of	  




Figure	  16.	  TNFa	  secretion	  from	  chronically	  treated	  macrophage	  group	  with	  high	  (100ng/ml)	  LPS	  




Figure	  17.	  TNFa	  secretion	  from	  chronically	  treated	  macrophage	  group	  with	  high	  (1ng/ml)	  LPS	  
alone	  for	  seven	  days	  or	  also	  receiving	  IFNg	  treatment	  at	  day	  six.	  Interaction	  was	  significant	  
(p=0.0225).  
	  
IFNg	  treatment	  of	  chronically	  stimulated	  macrophages:	  TNFa	  secretion	  from	  chronically	  
stimulated	  macrophages	  treated	  with	  LPS	  alone	  for	  seven	  days	  OR	  were	  given	  the	  same	  
treatment	  but	  with	  an	  additional	  IFNg	  treatment	  at	  day	  six,	  for	  24	  hours	  prior	  to	  collection.	  A)	  
TNFa	  protein	  secretion.	  The	  media	  was	  refreshed	  24	  hours	  prior	  to	  collection	  in	  all	  groups.	  Data	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collected	  from	  n=3	  experimental	  replicates	  and	  one	  biological	  replicates.	  Error	  bars	  are	  mean	  




To	  investigate	  if	  IFNg	  pre-­‐treatment	  impacted	  macrophages	  response	  to	  IL13/IL4,	  
CCL18,	  PDGFBB	  and	  TNFa	  protein	  secretion	  were	  analyzed	  at	  day	  seven	  of	  the	  (IFNg/LPS)	  
treated	  groups	  and	  at	  day	  eight	  of	  the	  same	  group	  which	  subsequently	  were	  exposed	  to	  
IL13/IL4	  treatment.	  IFNg	  pre-­‐	  treatment	  did	  not	  impact	  the	  decrease	  in	  TNFa	  secretion	  post	  
IL13/4	  treatment	  in	  groups	  primed	  using	  low	  LPS	  doses	  (Figure	  18;	  Figure	  	  21).	  However,	  TNFa	  
was	  significantly	  higher	  in	  pretreated	  groups	  that	  were	  primed	  with	  high	  LPS	  dose	  (Figure	  18).	  
Interestingly,	  IFNg	  pre-­‐treatment	  significantly	  enhanced	  CCL18	  fold	  change	  secretion	  in	  
response	  to	  IL13/4	  relative	  to	  untreated	  groups	  in	  acutely	  primed	  and	  M0	  groups,	  and	  impaired	  
chronically	  primed	  group	  (Figure	  19	  D).	  	  
PDGFBB	  secretion	  was	  impaired	  in	  all	  groups	  relative	  to	  untreated	  groups	  (Figure	  20).	  
These	  results	  suggest	  that	  IFNg	  pretreatment	  of	  chronically	  and	  acutely	  (high)	  primed	  
macrophages,	  enhanced	  CCL18	  secretion,	  impaired	  PDGFBB	  secretion,	  did	  not	  impact	  TNFa.	  
Chronically	  primed	  group	  impaired	  their	  CCL18	  and	  PDGFBB	  secretion	  in	  IFNg	  treated	  groups	  







Figure	  18.	  TNFa	  secretion:	  the	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
acutely	  stimulated	  macrophages	  
	  
Figure	  19.	  CCL18	  secretion:	  the	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
chronically	  stimulated	  macrophages	  with	  high	  LPS.	  	  
	  
	  
Figure	  20.	  PDGFBB	  secretion:	  the	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
chronically	  stimulated	  macrophages	  with	  high	  LPS.	  
The	  effect	  of	  IFNg	  pretreatment	  of	  chronically	  stimulated	  macrophages	  with	  high	  LPS	  on	  their	  
subsequent	  M1-­‐to-­‐M2	  switch:	  Chronically	  stimulated	  macrophages	  with	  high	  (100ng/ml)	  LPS	  
alone	  for	  seven	  days	  or	  with	  LPS	  alone	  for	  six	  days	  and	  LPS+(IFNg)	  during	  the	  seventh	  day.	  Then	  
all	  groups	  were	  exposed	  to	  IL13/IL4	  treatment	  for	  24	  hours	  until	  day	  eight.	  Each	  group	  was	  
compared	  to	  non-­‐IFNg	  treated	  control	  groups	  at	  day	  7	  and	  8.	  PDGFBB	  data	  collected	  from	  n=6	  
experimental	  replicates.	  CCL18	  and	  TNFa	  data	  collected	  from	  n=3	  experimental	  replicates.	  All	  
data	  are	  collected	  from	  one	  biological	  replicate.	  Error	  bars	  are	  mean	  +/-­‐	  SEM.	  Two	  way	  ANOVA	  
with	  Tukey’s	  post	  hoc	  was	  used	  to	  test	  the	  difference	  between	  IFNg	  and	  non-­‐IFNg	  treated	  












IFNg	  pre-­‐treatment	  significantly	  reduced	  CCL18	  fold	  change	  secretion	  in	  response	  to	  
IL13/4	  relative	  to	  untreated	  groups	  in	  acutely	  primed	  (low)	  macrophages	  (Figure	  22	  D).	  
Chronically	  primed	  group	  (low)	  had	  the	  greatest	  fold	  CCL18	  in	  response	  to	  IL13/IL4	  relative	  to	  
acute	  and	  M0	  macrophage	  groups.	  secretion	  was	  impaired	  in	  all	  groups	  relative	  to	  untreated	  
groups	  (Figure	  22).PDGFBB	  secretion	  was	  impaired	  in	  all	  IFNg	  treated	  groups	  relative	  to	  
untreated	  (Figure	  23).	  These	  results	  suggest	  that	  IFNg	  pretreatment	  of	  chronically	  and	  acutely	  
(high)	  primed	  macrophages,	  enhanced	  CCL18	  secretion,	  impaired	  PDGFBB	  secretion,	  did	  not	  
impact	  TNFa.	  Chronically	  primed	  group	  impaired	  their	  CCL18	  and	  PDGFBB	  secertion	  in	  IFNg	  









Figure	  21.	  TNFa	  secretion:	  The	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
chronically	  stimulated	  macrophages	  with	  low	  LPS.	  
 
 
Figure	  22.	  CCL18	  secretion:	  The	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
chronically	  stimulated	  macrophages	  with	  low	  LPS.Interaction	  was	  significant	  (p<0.0001)  
	  
Figure	  23.	  PDGFBB	  secretion:	  The	  effect	  of	  IFNg	  pre-­‐treatment	  on	  the	  M1-­‐to-­‐M2	  switching	  of	  
chronically	  stimulated	  macrophages	  with	  low	  LPS	  
The	  effect	  of	  IFNg	  pretreatment	  of	  chronically	  stimulated	  macrophages	  with	  low	  LPS	  on	  their	  
subsequent	  M1-­‐to-­‐M2	  switch:	  Chronically	  stimulated	  macrophages	  with	  low	  (1ng/ml)	  LPS	  
alone	  for	  seven	  days	  or	  with	  LPS	  alone	  for	  six	  days	  and	  LPS+(IFNg)	  during	  the	  seventh	  day.	  Then	  
all	  groups	  were	  exposed	  to	  IL13/IL4	  treatment	  for	  24	  hours	  until	  day	  eight.	  Each	  group	  was	  
compared	  to	  non-­‐IFNg	  treated	  control	  groups	  at	  day	  7	  and	  8.	  A)	  Protein	  secretion.	  B)	  Live	  cell	  
number	  using	  trypan	  exclusion	  assay.	  C)Protein	  secretion	  normalized	  to	  the	  average	  of	  live	  cell	  
number.	  Data	  collected	  from	  n=6	  biological	  replicates.	  Error	  bars	  are	  +/-­‐	  SEM.	  Two	  way	  ANOVA	  
with	  Tukey’s	  post	  hoc	  was	  used	  to	  test	  the	  difference	  between	  IFNg	  and	  non-­‐IFNg	  treated	  




In	  summary,	  these	  results	  suggest	  that	  regardless	  of	  the	  LPS	  chronic	  stimulation	  dose,	  
upon	  stimulation	  with	  IL4	  and	  IL13,	  the	  addition	  of	  IFNg	  impairs	  primed	  macrophages	  secretion	  
of	  PDGFBB,	  and	  does	  not	  affect	  the	  secretion	  of	  TNFa.	  Furthermore,	  upon	  stimulation	  with	  
IL4/IL13,	  chronically	  primed	  groups	  with	  high	  LPS	  dose	  pretreated	  with	  IFNg,	  did	  not	  change	  
their	  CCL18	  secretion.	  In	  contrast,	  chronically	  primed	  groups	  with	  low	  LPS	  dose	  that	  was	  
pretreated	  with	  IFNg,	  had	  an	  impaired	  CCL18	  secretion	  post	  IL13/IL4	  treatment.	  Last,	  IFNg	  
pretreatment	  always	  increased	  M0	  CCL18	  secretion	  upon	  IL13/IL4	  treatment.	  
	  
5.6.   Discussion	  
	  
The	  pretreatment	  with	  IFNg	  have	  been	  shown	  to	  partially	  overcome	  macrophage	  
hyporesponsiveness	  to	  a	  secondary	  dose	  of	  LPS	  in	  tolerant	  macrophages	  through	  blocking	  
tolerance	  mediated	  suppression	  of	  TNF-­‐a	  and	  IL-­‐659.	  Additionally,	  IFNg	  was	  shown	  to	  prolong	  
macrophages	  response	  to	  LPS	  rescue	  phagocytosis60.	  	  So,	  we	  tested	  if	  what	  was	  found	  to	  rescue	  
tolerance	  still	  holds	  true	  in	  the	  case	  of	  exhaustion.	  We	  hypothesized	  that	  IFNg	  may	  rescue	  
macrophages	  exhausted	  response	  to	  LPS	  induced	  by	  chronic	  LPS	  treatment.	  
Unexpectedly,	  IFNg	  was	  ineffective	  at	  rescuing	  the	  inflammatory	  response	  of	  chronically	  
stimulated	  groups	  characterized	  by	  their	  TNFa	  secretion.	  IFNg	  pre-­‐treatment	  impaired	  the	  
response	  of	  acutely	  stimulated	  macrophages	  to	  IL13/4	  by	  decreasing	  the	  CCL18	  and	  PDGFBB	  
secretion	  (Figure	  19;	  Figure	  20;	  Figure	  22;	  Figure	  23).	  	  
We	  speculate	  that	  IFNg	  treatment	  did	  not	  rescue	  the	  response	  of	  exhausted	  
macrophages	  to	  LPS	  because	  macrophages	  exhaustion	  maybe	  maintained	  by	  other	  negative	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suppression	  mechanisms	  that	  is	  different	  from	  the	  ones	  maintaining	  tolerance.	  However,	  it	  
impaired	  the	  secretion	  of	  M2	  associated	  proteins	  because	  of	  its	  STAT3	  suppressive	  roles63.	  	  
Future	  studies	  needs	  to	  investigate	  the	  mechanisms	  that	  mediates	  macrophage	  exhaustion	  and	  
possible	  treatments	  to	  overcome	  it.	  	  	  
The	  delivery	  of	  allogenic	  macrophages	  has	  been	  shown	  to	  improve	  chronic	  wounds’	  
healing99.	  Those	  allogenic	  macrophages	  are	  obtained	  from	  healthy	  and	  young	  people	  99.	  
However,	  due	  to	  the	  risks	  associated	  with	  cellular	  therapies,	  developing	  methods	  to	  rescue	  
endogenous	  exhausted	  macrophages	  will	  open	  the	  door	  for	  therapies	  that	  harness	  autologous	  
macrophages	  via	  restoring	  their	  proper	  responsiveness.	  
	  
6.   Limitations	  
 
Some	  limitations	  of	  this	  current	  work	  include	  the	  limited	  panel	  of	  proteins	  screened	  to	  
understand	  macrophages	  behavior.	  In	  future	  studies	  we	  aim	  to	  use	  a	  greater	  panel	  of	  proteins	  
and	  gene	  expansion	  analysis	  to	  gain	  a	  better	  understanding	  of	  the	  impact	  of	  chronic	  stimulation	  
on	  macrophage	  responsiveness	  to	  pro-­‐inflammatory	  and	  anti-­‐inflammatory	  stimuli.	  Moreover,	  
we	  hope	  to	  test	  the	  impact	  of	  macrophages	  chronic	  exposure	  to	  other	  pro-­‐inflammatory	  stimuli	  
that	  are	  common	  in	  some	  chronic	  diseases	  including	  TNFa	  and	  hyperglycemia.	  	  Last,	  we	  aim	  to	  
further	  understand	  the	  mechanisms	  of	  macrophage	  exhaustion	  to	  enable	  the	  development	  of	  
targeted	  strategies	  to	  rescue	  their	  response.	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In	  conclusion,	  our	  work	  suggests	  that	  macrophages	  chronic	  exposure	  to	  a	  high	  or	  low	  doses	  
of	  LPS	  leads	  to	  macrophage	  exhaustion	  characterized	  by	  a	  hyporesponsive	  behavior	  to	  
subsequent	  pro-­‐inflammatory	  stimulation.	  Importantly,	  acute	  and	  chronic	  LPS	  stimulation	  
enhanced	  their	  ability	  to	  polarize	  to	  the	  M2	  phenotype.	  	  	  
In	  each	  aim	  respectively,	  we	  showed	  that:	  	  
1)   Regardless	  of	  the	  starting	  time	  of	  stimulation,	  chronic	  LPS	  treatment	  	  impaired	  
macrophages	  TNFa	  secretion	  in	  response	  to	  fresh	  dose	  of	  LPS.	  	  
2)   Acute	  macrophages	  stimulation	  using	  a	  low	  dose	  of	  LPS	  does	  not	  impact	  macrophages	  
response	  to	  IL13/4.	  However,	  stimulating	  macrophages	  acutely	  with	  high	  LPS	  dose	  
impairs	  macrophages	  response	  to	  IL13/4.Also,	  chronic	  macrophage	  stimulation	  with	  LPS	  
enhanced	  their	  M2	  protein	  secretion	  in	  response	  to	  IL13/4.	  	  
3)   Pre-­‐treating	  chronically	  stimulated	  with	  IFNg,	  did	  not	  rescue	  their	  TNFa	  secretion.	  
However,	  it	  enhanced	  M0	  macrophage	  CCL18	  secretion	  and	  inhibited	  PDGBB	  secretion	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